{"filing":{"accession_number":"0001213900-26-085693","cik":"0001023549","ticker":"XTLB","company_name":"XTL BIOPHARMACEUTICALS LTD","form":"6-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"ea0300815-6k_xtlbiophar.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1023549/000121390026085693/ea0300815-6k_xtlbiophar.htm"},"events":[{"id":24105,"run_id":21813,"accession_number":"0001213900-26-085693","anchor_item_number":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"summary":"On August 3, 2026, XTL Biopharmaceuticals was served with a shareholder derivative motion in Israeli court alleging that the controlling shareholder and current/former directors breached fiduciary duties in connection with the 2024 acquisition of The Social Proxy Ltd., including alleged failures to fund the subsidiary, conflicts of interest, delayed disclosure, and financial irregularities. The petitioner seeks court authorization to file a derivative claim, monetary compensation estimated at approximately NIS 100 million, disgorgement, forensic accounting, and attorneys' fees. This is a material litigation disclosure involving substantial alleged damages and governance failures.","company_name":"XTL BIOPHARMACEUTICALS LTD","ticker":"XTLB","filing_date":"2026-08-05","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":24516,"accession_number":"0001213900-26-085693","item_number":null,"item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"On August 3, 2026, XTL Biopharmaceuticals was served with a shareholder derivative motion in Israeli court alleging that the controlling shareholder and current/former directors breached fiduciary duties in connection with the 2024 acquisition of The Social Proxy Ltd., including alleged failures to fund the subsidiary, conflicts of interest, delayed disclosure, and financial irregularities. The petitioner seeks court authorization to file a derivative claim, monetary compensation estimated at approximately NIS 100 million, disgorgement, forensic accounting, and attorneys' fees. This is a material litigation disclosure involving substantial alleged damages and governance failures.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-06T00:11:11.424727+00:00","company_name":"XTL BIOPHARMACEUTICALS LTD","ticker":"XTLB","filing_date":"2026-08-05"}]}